Loading...
Despite the promise of immune therapy for Alzheimer-type dementias, several approaches have failed. Now, industry-funded investigators report results on a newly developed, experimental monoclonal antibody, aducanumab.
In animal studies, aducanumab passed through the blood–brain barrier, attached to both soluble and insoluble amyloid, and decreased brain amyloid accumulations. In a human phase-1b double-blind, placebo-controlled, safety study, 165 participants with prodromal or mild Alzheimer disease intravenously received various aducanumab doses (1, 3, 6, or 10 mg/kg-1) or placebo, administered monthly for 1 year.
Dropouts occurred in 25% of the placebo group and 23% to 38% of the aducanumab subgroups (dropout rates increased at higher doses…